Teachers Retirement System of The State of Kentucky Makes New Investment in Xenon Pharmaceuticals Inc. $XENE

Teachers Retirement System of The State of Kentucky bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 21,133 shares of the biopharmaceutical company’s stock, valued at approximately $1,229,000.

A number of other institutional investors have also recently made changes to their positions in the company. Cinctive Capital Management LP grew its stake in shares of Xenon Pharmaceuticals by 1.1% during the 4th quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock worth $1,045,000 after acquiring an additional 263 shares during the period. State of Wyoming raised its stake in Xenon Pharmaceuticals by 30.4% in the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 350 shares during the period. Quarry LP lifted its holdings in Xenon Pharmaceuticals by 25.0% during the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 500 shares during the last quarter. Altfest L J & Co. Inc. lifted its holdings in Xenon Pharmaceuticals by 6.5% during the fourth quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 501 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in Xenon Pharmaceuticals by 11.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,574 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 675 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director directly owned 24,896 shares in the company, valued at $1,322,973.44. This represents a 5.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the transaction, the director directly owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. The trade was a 44.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Stock Up 0.6%

Shares of XENE opened at $67.71 on Thursday. The business’s 50-day moving average price is $56.79 and its 200-day moving average price is $51.60. Xenon Pharmaceuticals Inc. has a twelve month low of $30.00 and a twelve month high of $72.66. The stock has a market cap of $6.55 billion, a PE ratio of -14.41 and a beta of 0.61.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same quarter in the prior year, the business earned ($0.83) earnings per share. Analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

XENE has been the subject of several recent research reports. Royal Bank Of Canada lifted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Needham & Company LLC reduced their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. JPMorgan Chase & Co. boosted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a report on Wednesday, May 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $77.20.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.